All News
Filter News
Found 7,384 articles
-
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
11/8/2023
Revance Therapeutics, Inc. announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics.
-
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
11/8/2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2023.
-
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
11/8/2023
Kamada Ltd. today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023.
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
11/8/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2023.
-
For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.
-
The Department of Health and Human Services in a court filing last week said that the blockbuster treatment could be “deselected” from the drug price negotiation list, given the recent approval of Amgen’s Stelara biosimilar.
-
Amneal Reports Third Quarter 2023 Financial Results
11/7/2023
Amneal Pharmaceuticals, Inc. announced its results for the third quarter ended September 30, 2023.
-
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
11/7/2023
Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
-
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
11/7/2023
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental Biologics License Application (sBLA) for the interchangeability designation for HADLIMA™ (adalimumab-bwwd) injection 40 mg/0.4 mL, a biosimilar to Humira® (adalimumab).
-
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
11/7/2023
Alvotech announced its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023.
-
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
11/7/2023
Teva Pharmaceutical Industries Ltd. announced the appointment of Dr. R. Ananthanarayanan as CEO of its Teva Active Pharmaceutical Ingredients business.
-
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
11/7/2023
Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's.
-
Biogen Appoints Monish Patolawala to its Board of Directors
11/6/2023
Biogen Inc. announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company, to the Company’s Board of Directors, effective January 1, 2024.
-
Revance to Participate in Upcoming Investor Conferences - November 6, 2023
11/6/2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.
-
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
11/6/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights.
-
Amneal to Participate at Upcoming November 2023 Investor Conferences
11/3/2023
Amneal Pharmaceuticals, Inc. announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the below investor conferences.
-
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
11/3/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.
-
Ahead of the Inflation Reduction Act’s drug price negotiations, the regulator has approved Amgen’s biosimilar challenge to Johnson & Johnson’s Stelara—with an interchangeable designation to boot.
-
Organon Reports Results for the Third Quarter Ended September 30, 2023
11/2/2023
Organon announced its results for the third quarter ended September 30, 2023.
-
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis
11/2/2023
Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.